Evidence map›Paper›PMID 36940616›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2023

Piperlongumine inhibits proliferation and oncogenic MYCN expression in chemoresistant metastatic retinoblastoma cells directly and through extracellular vesicles.

Cui Shi, Kunhui Huang, John Soto, Renuka Sankaran, Vrinda Kalia, Onyekwere Onwumere, Michael Young, Linda Einbond, Stephen Redenti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Cui ShiLehman College, the City University of New York, 250 Bedford Park Boulevard West, Bronx, NY 10468, USA; Biochemistry Doctoral Program, The Graduate School, City University of New York, 365 Fifth Avenue, New York, NY 10016, USA.
Kunhui HuangLehman College, the City University of New York, 250 Bedford Park Boulevard West, Bronx, NY 10468, USA; Biochemistry Doctoral Program, The Graduate School, City University of New York, 365 Fifth Avenue, New York, NY 10016, USA.
John SotoLehman College, the City University of New York, 250 Bedford Park Boulevard West, Bronx, NY 10468, USA.
Renuka SankaranLehman College, the City University of New York, 250 Bedford Park Boulevard West, Bronx, NY 10468, USA; Biochemistry Doctoral Program, The Graduate School, City University of New York, 365 Fifth Avenue, New York, NY 10016, USA.
Vrinda KaliaDepartment of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, NY 10032, USA.
Onyekwere OnwumereLehman College, the City University of New York, 250 Bedford Park Boulevard West, Bronx, NY 10468, USA; Biology Doctoral Program, The Graduate School of the City University of New York, 365 5th Avenue, New York, NY 10016, USA.
Michael YoungThe Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA.
Linda EinbondLehman College, the City University of New York, 250 Bedford Park Boulevard West, Bronx, NY 10468, USA.
Stephen RedentiLehman College, the City University of New York, 250 Bedford Park Boulevard West, Bronx, NY 10468, USA; Biochemistry Doctoral Program, The Graduate School, City University of New York, 365 Fifth Avenue, New York, NY 10016, USA; Biology Doctoral Program, The Graduate School of the City University of New York, 365 5th Avenue, New York, NY 10016, USA. Electronic address: Stephen.Redenti@lehman.cuny.edu.
The Graduate Center, CUNY · USLehman College · USColumbia University · USMassachusetts Eye and Ear Infirmary · US

Funding

Modeling Photoreceptor Migration in Biomimetic Microenvironments to Optimize TransplantationSC3GM113782 · NIGMS · HERBERT H. LEHMAN COLLEGE · PI REDENTI, STEPHEN M · 2015 to 2024
$898k
Photoreceptor integration via chemotactic honingR21EY026752 · NEI · CITY COLLEGE OF NEW YORK · PI VAZQUEZ, MARIBEL · 2016 to 2017
$431k
NEI NIH HHS R21 EY026752NIGMS NIH HHS SC3 GM113782
6 · The paper itself

Abstract

Ocular retinoblastoma malignancies, which develop into metastatic phenotypes, result in poor prognosis and survival for infant and child patients. To improve the prognosis of metastatic retinoblastoma, it is important to identify novel compounds with less toxic side effects and higher therapeutic efficacy compared to existing chemotherapeutics. Piperlongumine (PL), a neuroprotective, plant-derived compound has been explored for its anticancer activities both in vitro and in vivo. Here, we analyze the potential efficacy of PL for metastatic retinoblastoma cell treatment. Our data reveal that PL treatment significantly inhibits cell proliferation in metastatic retinoblastoma Y79 cells compared to the commonly used retinoblastoma chemotherapeutic drugs carboplatin, etoposide, and vincristine. PL treatment also significantly increases cell death compared to treatment with other chemotherapeutic drugs. PL-induced cell-death signaling was associated with significantly higher caspase 3/7 activities and greater loss of mitochondrial membrane potential. PL was also internalized into Y79 cells with an estimated concentration of 0.310pM and expression analysis revealed reduced MYCN oncogene levels. We next examined extracellular vesicles derived from PL-treated Y79 cells. Extracellular vesicles in other cancers are pro-oncogenic, mediating systemic toxicities via the encapsulation of chemotherapeutic drugs. Within metastatic Y79 EV samples, an estimated PL concentration of 0.026pM was detected. PL treatment significantly downregulated Y79 EV cargo of the oncogene MYCN transcript. Interestingly, non-PL-treated Y79 cells incubated with EVs from PL-treated cells exhibited significantly reduced cell growth. These findings indicate that in metastatic Y79 cells, PL exhibits potent anti-proliferation effects and oncogene downregulation. Importantly, PL is also incorporated into extracellular vesicles released from treated metastatic cells with measurable anti-cancer effects on target cells at a distance from the site of primary treatment. The use of PL in the treatment of metastatic retinoblastoma may reduce primary tumor proliferation and inhibit metastatic cancer activity systemically via extracellular vesicle circulation.

Indexed as

Retinal NeoplasmsRetinoblastomaCell Line, TumorCell ProliferationHumansN-Myc Proto-Oncogene ProteinPiperidonesMYCN protein, humanN-Myc Proto-Oncogene ProteinPiperidonespiperlongumineChemoresistanceChemotherapeutic drugsExtracellular vesiclesMetastatic retinoblastomaMYCNPiperlongumine

Identifiers

PMID36940616
PMCPMC10157982
OpenAlexW4327976851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.